Alcon (NYSE: ALC)
Alcon Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Alcon Company Info
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.
News & Analysis
FDA Approves 3 Drugs for the Switch From Prescription to Over the Counter
The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.
What Happened in the Stock Market Today
Novartis completed its spin-off of eye care specialist Alcon and Zogenix had a drug application rejection.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.